Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

BMC Pediatrics

Tatsuo Fuchigami¹  Koji Hashimoto¹  Yayoi Yoshino¹  Teruaki Ishikawa¹  Osamu Abe¹  Takahiro Nakamura¹  Rika Hayashi¹  Maki Hasegawa¹  Katsuya Saito¹  Yasuji Inamo¹ 

[1] Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan

关键词: IVIG;    Angiogenesis;    Coronary artery disease;    Dalteparin;    Low-molecular-weight heparin;    Kawasaki disease;   

Others  :  1143889
DOI  :  10.1186/1471-2431-14-27

 received in 2013-10-09, accepted in 2014-01-29,  发布年份 2014

【 摘 要 】

Background

Dalteparin, a low-molecular-weight heparin, has anticoagulant and anti-angiogenic activity. This study investigated whether dalteparin reduced coronary artery lesion (CAL) prevalence, and resistance to intravenous immunoglobulin (IVIG) therapy in Kawasaki disease (KD).

Methods

This retrospective study comprised two parts. In the first cohort, 126 patients with KD (68 male, 58 female; median age: 22 months, range: 1–67 months) admitted to Nihon University Nerima-Hikarigaoka Hospital from January 2004 to June 2008, received either dalteparin 75 IU/kg/day, IVIG 400 mg/kg/day for 5 consecutive days, and aspirin 30 mg/kg/day, or dalteparin 75 IU/kg/day and aspirin 30 mg/kg/day, until clinical improvement. Control data came from the 2005–6 Nationwide KD survey. In the second cohort, 112 patients with KD (59 male, 53 female; median age: 19 months, range: 1–66 months) admitted from June 2010 to February 2012, received either dalteparin 75 IU/kg/day, IVIG 2.0 g/kg over 12 h, and aspirin 30 mg/kg/day, or dalteparin 75 IU/kg/day and aspirin 30 mg/kg/day. Control data came from the 2009–10 Nationwide KD survey. No patients enrolled in the nationwide surveys received dalteparin. All patients at our institution were given dalteparin in their combination therapy.

Results

A comparison of the first cohort with controls in the nationwide survey showed that the prevalence of initial administration of IVIG was 80.2% versus 86.0%; the rate of additional IVIG administration was 7.1% versus 14.0% (p = 0.03); CAL prevalence in the acute period was 4.8% versus 11.9% (p < 0.01); and the prevalence of cardiovascular sequelae was 0% versus 3.8% (p < 0.05). A comparison of the second cohort with controls in the nationwide survey showed that the rate of initial administration of IVIG was 92.9% versus 89.5%; the rate of additional IVIG administration was 8.9% versus 17.1% (p = 0.02); the prevalence of resistance to IVIG was 3.6% versus 14.9% (p < 0.001); and CAL prevalence in the acute period was 2.7% versus 8.6% (p = 0.03).

Conclusions

This study found that adjunctive dalteparin was associated with a lower prevalence of IVIG resistance and CAL in young children with KD.

Trial registration

UMIN-CTR: UMIN000010349.

【 授权许可】

   
2014 Inamo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Durongpisitkul K, Gururaj VJ, Park JM, Martin CF: The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995, 96(6):1057-1061.
• [2]Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, et al.: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324(23):1633-1639.
• [3]Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, Kotani K, Tsogzolbaatar EO, Yanagawa H: Epidemiologic features of Kawasaki disease in Japan: results of the 2009–2010 nationwide survey. J Epidemiol 2012, 22(3):216-221.
• [4]Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, Newburger JW: Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009, 124(1):1-8.
• [5]Breunis WB, Davila S, Shimizu C, Oharaseki T, Takahashi K, van Houdt M, Khor CC, Wright VJ, Levin M, Burns JC, et al.: Disruption of vascular homeostasis in patients with Kawasaki disease: involvement of vascular endothelial growth factor and angiopoietins. Arthritis Rheum 2012, 64(1):306-315.
• [6]Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y: Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999, 83(3):337-339.
• [7]Ebata R, Abe J, Yasukawa K, Hamada H, Higashi K, Suwazono Y, Saito H, Terai M, Kohno Y: Increased production of vascular endothelial growth factor-d and lymphangiogenesis in acute Kawasaki disease. Circ J 2011, 75(6):1455-1462.
• [8]Takeshita S, Kawamura Y, Takabayashi H, Yoshida N, Nonoyama S: Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clin Exp Immunol 2005, 139(3):575-579.
• [9]Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, Rowley AH: Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002, 105(6):766-769.
• [10]Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 2008, 121(5):637-645.
• [11]Norrby K, Nordenhem A: Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. Apmis 2010, 118(12):949-957.
• [12]Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol 2005, 146(3):333-343.
• [13]Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M: Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)–a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 1993, 72(6):475-500.
• [14]Manlhiot C, Brandao LR, Somji Z, Chesney AL, MacDonald C, Gurofsky RC, Sabharwal T, Chahal N, McCrindle BW: Long-term anticoagulation in Kawasaki disease: initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities. Pediatr Cardiol 2010, 31(6):834-842.
• [15]Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, Ishii M, Harada K: Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005, 47(2):232-234.
• [16]Harada K: Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991, 33(6):805-810.
• [17]Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H: Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005–2006. J Epidemiol 2008, 18(4):167-172.
• [18]Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)--digest version Circ J 2010, 74(9):1989-2020.
• [19]Bratincsak A, Reddy VD, Purohit PJ, Tremoulet AH, Molkara DP, Frazer JR, Dyar D, Bush RA, Sim JY, Sang N, et al.: Coronary artery dilation in acute Kawasaki disease and acute illnesses associated with Fever. Pediatr Infect Dis J 2012, 31(9):924-926.
• [20]Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, et al.: Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012, 379(9826):1613-1620.
• [21]Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, et al.: Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation 2011, 124(25):2822-2828.
• [22]Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, et al.: Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153(6):833-838.